Skip to main content

Xiamen Spacegen Receives CE Marking for Six Molecular Testing Kits

NEW YORK (GenomeWeb) – Xiamen Spacegen, a provider of oncology molecular diagnostics products and services in China, said today that it has received CE marking for six testing kits.

These kits include a human thyroid carcinoma RET gene fusions detection kit, which is run on a multiplex fluorescence PCR platform; a human MGMT gene methylation detection kit, also run on multiplex fluorescence PCR; and a human EGFR gene T790M mutation detection kit, based on digital PCR technology.

The company also garnered CE marking for three tests based on high-throughput sequencing: a human pharmacogenomics SNP detection kit; a human radiotherapeutic side effect-related gene SNP detection kit; and a cardiotoxicity prediction of breast cancer detection kit.

Spacegen said that these new approvals mean it now has 11 products with CE marking, including kits for multi-gene mutations, BRCA mutations, EGFR mutations, KRAS mutations, and BRAF mutations. The firm also noted that it has applied for CE certification for additional products that it has developed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.